Recursion Pharmaceuticals
RXRX
RXRX
312 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 84 funds opening new positions, 114 increasing their positions, 60 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
312
Holders Change
+48
Holders Change %
+18.18%
% of All Funds
4.15%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
84
Increased
114
Reduced
60
Closed
33
Calls
$30.7M
Puts
$30.9M
Net Calls
-$211K
Net Calls Change
+$8.19M
Top Buyers
| 1 |
SoftBank Group
Tokyo,
Japan
|
$99.2M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
$68.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
$230M |
| 4 |
BlackRock
New York
|
$158M |
| 5 |
Citadel Advisors
Miami,
Florida
|
$18.5M |
